###### Strengths and limitations of this study

-   This is a prospective study design with an ethnically diverse, large-scale elderly population with chronic kidney disease (CKD) across China.

-   A broad range of candidate risk factors will be monitored, especially non-disease-specific problems that are common in the elderly but are not traditionally considered.

-   A limitation is that we recruited subjects based on a single measure of serum creatinine and/or albuminuria without a 3-month interval.

-   There is no uniformed, standardised creatinine assay, and the CKD-Epidemiology Collaboration equation remains imperfect in elderly persons, as it is affected by loss of muscle mass.

-   Some elderly patients with CKD are excluded from the study (eg, because of inability to comply), and therefore the results of the study may not be completely generalisable to all elderly patients with CKD.

Introduction {#s1}
============

The percentage of people who are elderly is increasing worldwide. By 2050, the population older than 60 years is expected to double, from 11% to 22%.[@R1] This phenomenon is also true of countries with populations that are predominantly of low income and middle income.[@R2] In China in 2010, the number of people 60 years or older had already reached 177 million, according to the national census.[@R3] An ageing population has important implications for medical care and public health systems.

Chronic kidney disease (CKD), characterised by poor health outcomes and high healthcare costs, is very common among the elderly. The National Health and Nutrition Examination Survey showed that the prevalence of CKD is 38% among those aged \>65 years, compared with 13% of the overall US population.[@R4]

Risk modification in elderly patients with CKD is often challenging because of the heterogeneity of disease and the competing risks of other adverse events.[@R5] While younger patients with CKD may progress to end-stage renal disease (ESRD), elderly patients are more likely to suffer mortality than progress to ESRD.[@R6] The condition of older adults with CKD is often complicated by comorbidities and their associated adverse outcomes,[@R7] and the CKD population has a high prevalence of geriatric syndromes that include frailty, cognitive impairment and impaired mobility.

These findings suggest that clinical decisions regarding older patients cannot be based on either chronological age alone, or factors such as elevated creatinine and proteinuria traditionally used to monitor kidney function. More comprehensive management is required, covering medical, functional and psychosocial problems. However, there are very little data on the management of these domains and associated outcomes of elderly patients with CKD, and the current clinical guidelines often focus on specific renal diseases, but fail to consider overtly the contribution and implication of non-disease-specific problems.

For these reasons, we established a national cohort of Chinese elderly patients with CKD to enable prospective observational studies. The goals are the following:To complete an epidemiological survey of CKD in the elderly across China, and evaluate the prevalence, distribution, aetiology and comorbidity patterns of CKD in this population.To conduct a comprehensive geriatric assessment among older patients with CKD, including cognitive function, depressive symptoms, diet and nutrition, functional status, and quality of life. We aim to determine the prevalence of these non-disease-specific problems of older adults with CKD and to investigate their impact on outcomes.To explore both traditional and non-traditional risk factors that are associated with adverse clinical outcomes. Traditional risk factors are those that have been well studied in renal disease, such as blood pressure and proteinuria. Non-traditional risk factors are more common among the elderly, but have been little considered in renal disease. Identifying these factors should aid the development of predictive models of subgroups of older patients with CKD who are at high risk.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

This study is a multicentre, prospective cohort study of Chinese elderly with CKD, sponsored by the National Clinical Research Center for Kidney Disease at People's Liberation Army (PLA) General Hospital, located in Beijing, China. All of the participating clinical centres are renal departments at 34 hospitals, located in 26 cities in 24 provinces of China.

Study population {#s2b}
----------------

Recruitment of a baseline cohort of \~3000 participants was conducted between March 2016 and November 2017. The participants will be followed up until the occurrence of a primary outcome or 5 years after enrolment.

The cohort of elderly patients is racially and ethnically diverse, with a broad spectrum of renal disease severity. All the participants conform to the following inclusion criteria: aged ≥65 years old, received a diagnosis of CKD and provided signed informed consent.

We exclude participants if they (1) are participating in other interventional clinical trials; (2) had ESRD or receiving dialysis; (3) are diagnosed as having acute kidney injury; (4) had a history of renal or other transplantation; (5) had active malignancy within 24 months prior to screening, or metastatic cancer; (6) had a life expectancy less than 6 months; (7) had severe heart failure (New York Heart Association function class III or IV); (8) had HIV infection; (9) had isolated haematuria; and (10) were unable to communicate with examiners, unable to complete the study procedure even if assisted and otherwise unable to comply with the study protocol.

Diagnostic criteria for CKD {#s2c}
---------------------------

The diagnosis of CKD is based on the criteria of the 2012 Kidney Disease: Improving Global Outcomes, that is, a single measurement showing glomerular filtration rate (GFR) \<60 mL/min/1.73 m^2^ or proteinuria (albumin excretion rate ≥30 mg/day or albumin to creatinine ratio (ACR) ≥30 mg/g),[@R10] or both.

The estimated GFR (eGFR, reported as mL/min/1.73 m^2^) is calculated according to the serum creatinine (Scr) level obtained using either Jaffe's kinetic method or the Roche enzymatic method. If via Jaffe's kinetic method, the Modification of Diet in Renal Disease equation is adapted to data specific to Chinese patients with CKD: eGFR (mL/min/1.73 m^2^)=175×Scr^−1.234^×Age^−0.179^ (×0.79, if female), with age in years.[@R11]

Alternatively, if the Scr is measured by the Roche enzymatic method, the GFR is evaluated by the CKD-Epidemiology Collaboration creatinine equation,[@R12] with age in years, as follows:

$$\begin{matrix}
{{eGFR\ (mL/min/1.73\ m^{2})} =} & {{144 \times (Scr/0.7)^{- 0.329}} \times 0.993^{Age}} \\
 & {(female,\ Scr \leq 0.7\ mg/dL)} \\
\end{matrix}$$

$$\begin{matrix}
{{eGFR\ (mL/min/1.73\ m^{2})} =} & {144 \times (Scr/0.7)^{- 1.209} \times 0.993^{Age}} \\
 & {(female,\ Scr > 0.7\ mg/dL)} \\
\end{matrix}$$

$$\begin{matrix}
{{eGFR\ (mL/min/1.73\ m^{2})} =} & {141 \times (Scr/0.9)^{- 0.411} \times 0.993^{Age}} \\
 & {(male,\ Scr \leq 0.9\ mg/dL)} \\
\end{matrix}$$

$$\begin{matrix}
{{eGFR\ (mL/min/1.73\ m^{2})} =} & {141 \times (Scr/0.9)^{- 1.209} \times 0.993^{Age}} \\
 & {(male,\ Scr > 0.9\ mg/dL)} \\
\end{matrix}$$

Study protocol {#s2d}
--------------

The study protocol consists of three main steps ([figure 1](#F1){ref-type="fig"}): screening and enrolment, baseline visit, and follow-up visits.

![Flow chart of study design and procedures. eGFR, estimated glomerular filtration rate; Scr, serum creatinine.](bmjopen-2017-019457f01){#F1}

### Screening and enrolment {#s2d1}

The screening of potential subjects is conducted by nephrologists at each clinical centre to assess the eligibility for the study according to the inclusion and exclusion criteria. When eligible, subjects signed informed consent forms before officially entering the study.

### Baseline visit {#s2d2}

On acceptance into the study, demographic information, laboratory parameters, anthropomorphic measures and questionnaires are collected from each patient.

Detailed demographic and clinical data include age, gender, ethnicity, residence, education, marital status, occupational status, income, housing, alcohol intake, smoking history, clinical aetiology of CKD (if known), comorbidities, medical history and use of medication.

Anthropomorphic measures include height, weight, waist circumference, hip and mid-arm circumference, triceps skinfold thickness, blood pressure, heart rate, handgrip strength and 5 m measured walk.

Laboratory items include full blood count, blood chemistry, haemoglobin A1c test for diabetes, routine and 24-hour urine, medical imaging, and others ([table 1](#T1){ref-type="table"}). There are some other special tests, such as pulse wave velocity and ankle-brachial index, that could not be conducted at all clinical centres, but will be performed in some centres as ancillary research.

###### 

Baseline laboratory items/parameters for enrolled participants

  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Full blood count   Red blood cell, white blood cell, haemoglobin, neutrophilic granulocyte percentage, platelet count, red blood cell distribution width
  Chemistry          Scr, uric acid, albumin, BUN, carbon dioxide, glucose, serum potassium, calcium, phosphate, serum sodium, chloride, prealbumin, transferrin, total iron binding capacity, cholinesterase, homocysteine, lipid panel[\*](#tblfn1){ref-type="fn"}
  HbA1c              HbA1c (for diabetes)
  Routine urine      Urine dipstick
  24-Hour urine      Urine protein, electrolytes
  Other items        Intact PTH, cystatin C, hs-CRP, ACR
  Imaging            ECG, carotid artery ultrasound, echocardiogram, ABPM, BIA, lateral abdominal radiograph
  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Lipid panel includes total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein cholesterols.

ABPM, ambulatory blood pressure monitoring; ACR, albumin to creatinine ratio; BIA, bioelectrical impedance analysis; BUN, blood urea nitrogen; HbA1c, haemoglobin A1c; hs-CRP, high-sensitivity C reactive protein; PTH, parathyroid hormone; Scr, serum creatinine.

Questionnaires on cognitive function, depressive symptoms, risk of malnutrition, functional and physical impairment, and health-related quality of life (HRQOL) are also collected (described below).

Assessments based on questionnaires {#s2e}
-----------------------------------

### Cognitive function {#s2e1}

The Montreal Cognitive Assessment (MoCA) is an evaluation scale used to screen for mild cognitive impairment (MCI)[@R13] in elderly adults[@R14] but is not valid for illiterate or those with little education.[@R15] Thus, a revised MoCA test, the MoCA basic (MoCA-B), was developed.[@R17] Given that China has a large proportion of elderly adults with little education, we chose the Chinese version of the MoCA-B (MoCA-BC) to screen for MCI. The MoCA-BC assesses nine cognitive domains: executive function, language, orientation, calculation, conceptual thinking, memory, visual perception, attention and concentration. The MoCA-BC is a screening tool that has been proven reliable in detecting MCI across all educational levels in Chinese elderly adults, with high acceptance and good reliability.[@R18]

### Psychological measures {#s2e2}

Symptoms of depression are assessed using the 15-item Geriatric Depression Scale (GDS-15), a reliable and well-validated measure of depressive symptoms in elderly patients.[@R19] It has been validated for use in local Chinese, Malay and Indian subjects.[@R20] This self-administered questionnaire contains 15 yes/no questions. Scores range from 0 to 15, and higher scores indicate more severe depression.

### Risk of malnutrition {#s2e3}

Risk of malnutrition was measured according to the Malnutrition Inflammation Score (MIS), which was developed for patients on maintenance haemodialysis.[@R22] It contains 10 items derived from medical history, physical examinations, body mass index and laboratory parameters. Each component is scored from 0 (normal) to 3 (severely abnormal). It has been reported that a revised MIS appears to be a useful tool to assess nutritional states and the essence of the protein-energy wasting (PEW), and to predict mortality risk in non-dialysed patients with CKD.[@R23] In the validated MIS scale, dialysis vintage (ie, length of time on dialysis) was excluded from the score. Comorbidity was scored as follows: 0, no other medical illnesses; 1, mild comorbidity; 2, moderate comorbidity (including one of the major comorbid conditions); and 3, ≥2 major comorbid conditions. In the present study, major comorbid conditions include congestive heart failure class III or IV, severe coronary artery diseases, moderate-to-severe chronic obstructive pulmonary disease or major neurological sequels. Serum transferrin was used instead of total iron binding capacity.

### Assessment of functional disability {#s2e4}

Functional and physical impairments are assessed using the Activity of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL) scales. The ADL scale assesses self-maintaining activities of daily living, including feeding, dressing, grooming, transferring, mobility, stairs, and toilet use including bowel and bladder, and bathing.[@R24] The IADL scale evaluates complex activities, including performance in transportation, preparing meals, taking medicine, housework, laundry, shopping, using telephone, managing finance and staying alone at home. Each item within the activities domains is scored from 0 to 4.

### Quality of life {#s2e5}

Health-related quality of life (HRQOL) is assessed using the Kidney Disease Quality of Life-36 (KDQOL-36) instrument.[@R25] KDQOL-36 was introduced in 1994 and is specific to kidney disease. The five subscales of the KDQOL-36 are mental component summary, physical component summary, burden of kidney disease, effects of kidney disease, and symptoms and problems of kidney disease.[@R26] Low HRQOL is defined as a KDQOL-36 baseline score that is \>1 SD below the mean.

### Follow-up visit {#s2e6}

Subsequent to the baseline evaluation, follow-up visits will be conducted over the study period to monitor study outcomes, update contact information and repeat the baseline assessments ([table 2](#T2){ref-type="table"}). All efforts are made to prevent dropout from the programme.

###### 

Items and procedures of the study at baseline and each follow-up

  --------------------------------------------------------------------------------------------------------------------------------------------------
                                                         0 month   6 months\   12 months\   18 months\   2 years\   3 years\   4 years\   5 years\
                                                                   ±30 days    ±30 days     ±30 days     ±30 days   ±30 days   ±30 days   ±30 days
  ------------------------------------------------------ --------- ----------- ------------ ------------ ---------- ---------- ---------- ----------
  Informed consent                                       ×         --          --           --           --         --         --         --

  Inclusion/exclusion criteria                           ×         --          --           --           --         --         --         --

  Physical examination                                   ×         ×           ×            ×            ×          ×          ×          ×

  Anthropomorphic measures[\*](#tblfn3){ref-type="fn"}   ×         ×           ×            ×            ×          ×          ×          ×

  Blood cellular evaluation                              ×         ×           ×            ×            ×          ×          ×          ×

  Blood biochemical analysis                             ×         ×           ×            ×            ×          ×          ×          ×

  Serum electrolytes                                     ×         ×           ×            ×            ×          ×          ×          ×

  Routine urine test                                     ×         ×           ×            ×            ×          ×          ×          ×

  24-Hour urine protein                                  ×         ×           ×            ×            ×          ×          ×          ×

  24-Hour urine electrolytes                             ×         --          ×            --           ×          ×          ×          ×

  Urinary albumin to creatinine ratio                    ×         ×           ×            ×            ×          ×          ×          ×

  Intact PTH                                             ×         --          ×            --           ×          ×          ×          ×

  Cystatin C                                             ×         ×           ×            ×            ×          ×          ×          ×

  hs-CRP                                                 ×         --          ×            --           ×          ×          ×          ×

  Electrocardiography                                    ×         --          ×            --           ×          ×          ×          ×

  Carotid artery ultrasound                              ×         --          ×            --           ×          ×          ×          ×

  Echocardiogram                                         ×         --          ×            --           ×          ×          ×          ×

  ABPM                                                   ×         --          ×            --           ×          ×          ×          ×

  BIA                                                    ×         --          ×            --           ×          ×          ×          ×

  Lateral abdominal radiograph                           ×         --          ×            --           ×          ×          ×          ×

  Demographic data and medical history                   ×         --          --           --           --         --         --         --

  Sample collection                                      ×         --          ×            --           ×          ×          ×          ×

  ADL                                                    ×         --          ×            --           ×          ×          ×          ×

  KDQOL-36                                               ×         --          ×            --           ×          ×          ×          ×

  MIS                                                    ×         ×           ×            ×            ×          ×          ×          ×

  GDS-15                                                 ×         --          ×            --           ×          ×          ×          ×

  MoCA                                                   ×         --          --           --           --         --         --         ×

  Drug collected                                         ×         ×           ×            ×            ×          ×          ×          ×

  Adverse events                                         ×         ×           ×            ×            ×          ×          ×          ×

  Clinical outcomes                                      --        ×           ×            ×            ×          ×          ×          ×
  --------------------------------------------------------------------------------------------------------------------------------------------------

x, item that will be collected.

-, item that will not be collected.

\*Anthropomorphic measures: height, weight, waist circumference, hip circumference, mid-arm circumference, triceps skinfold thickness, blood pressure, heart rate, handgrip strength and 5 m measured walk.

ABPM, ambulatory blood pressure monitoring; ADL, Activity of Daily Living scale; BIA, bioelectrical impedance analysis; GDS, Geriatric Depression Scale; hs-CRP, high-sensitivity C reactive protein; KDQOL-36, Kidney Disease Quality of Life-36; MIS, malnutrition inflammation score; MoCA, Montreal Cognitive Assessment; PTH, parathyroid hormone.

Blood and urine samples collection {#s2f}
----------------------------------

Blood specimen, morning urine and 24-hour urine samples were collected at the baseline assessment and will be collected at the follow-ups. After simple processing, the specimens are frozen at −80°C at each participating centre, and then transported to the central laboratory by cold chain every 3 months for future use.

With these specimens, we intend to explore for novel biomarkers that reflect CKD progression and develop predictive models to identify a subgroup population among elderly persons with CKD who are at high risk. Examples of biomarkers to explore include vascular endothelial progenitor cells, klotho protein, markers of muscle consumption, the senescence index silent information regulator T1 and telomere length.

Study outcomes {#s2g}
--------------

The primary outcomes of this study are all-cause mortality incidence of ESRD (ie, GFR \<15 mL/min/1.73 m^2^, or start of dialysis or renal transplantation) and loss of renal function (≥40% decline in GFR from baseline), with GFR confirmed at intervals of no less than 4 weeks.

The secondary endpoints include acute myocardial infarction, hospitalisation for congestive heart failure or unstable angina, cerebrovascular events (intracranial haemorrhage, subarachnoid haemorrhage, ischaemic stroke), and peripheral arterial disease. Acute myocardial infarction is defined as elevated levels of cardiac enzymes accompanied by symptoms such as a sudden painful sensation of pressure in the chest, profuse perspiration, nausea and vomiting, changes on ECG compatible with ischaemia or infarction,[@R27] or new fixed perfusion abnormalities with corroborating wall motion.

Congestive heart failure is defined as hospitalisation for new or abrupt worsening of signs and symptoms and signs combined with falling cardiac output. Unstable angina is considered \>10 min of ischaemic symptoms that cannot be relieved by nitrate drugs, combined with new or aggravated ECG changes or imaging evidence of myocardial ischaemia, without changes of myocardial necrosis markers. Cerebrovascular events are diagnosed based on symptoms and changes of cranial CT scan or head MRI. Peripheral vascular disease is defined as amputation resulting from vascular disease or peripheral surgical or percutaneous revascularisation, or amputation resulting from vascular disease.

Suspected endpoint events will be determined by an independent assessment committee. In addition, an electronic database will be established, through which the Chinese PLA General Hospital could periodically supervise all participants to ensure complete information and input of outcome events. The determination of outcomes will also be supplemented by reports from patient proxies, hospital medical records and death certificates.

Data analysis plan {#s2h}
------------------

Continuous variables will be presented as mean±SD. Normally distributed variables will be compared using the Student's t-test. Non-parametric variables will be assessed by Mann-Whitney U test. Categorical variables will be presented as percentages and compared using the χ^2^ test.

There are several study endpoints, such as failure times including ESRD, reduction in eGFR and mortality. Kaplan-Meier curves, log-rank tests and the multivariate Cox proportional hazards analysis will be used to evaluate the associations between various baseline variables and study outcomes.[@R28]

Subgroup analyses will be conducted across different baseline eGFR level, proteinuria level and CKD aetiology, if needed. Receiver operating characteristic (ROC) curves will be used to evaluate the outcome predictability of baseline parameters by comparing the areas under the ROC curve, and to set the cut-offs of baseline parameters to predict renal outcomes in different subgroups.

Analysis of variables with repeated measures, such as eGFR, will use standard mixed effects growth curve models supplemented by generalised estimating equations. The characteristics of subjects without complete follow-up will also be analysed, and factors associated with dropout will be analysed.

A P value \<0.05 will be considered statistically significant.

Sample size {#s2i}
-----------

The sample size for this study was calculated at 3000 participants with the following reasoning: We selected all-cause mortality as the primary study outcomes to calculate the sample size. Some studies have reported the mortality of older patients with CKD. Among 828 individuals older than 65 years, with eGFR \<60 mL/min per 1.73 m^2^, there were 283 deaths (34%) over 5 years.[@R29] Another study revealed that the mortality rate was 125/1000 patient-years and the ESRD rate was 63/1000 patient-years during a median follow-up of 3.3 years.[@R30]

On the basis of previous validation data and our own experience, we estimated that the incidence rate of mortality at 60 months of follow-up was at ≥10%. There are 20--25 variables that may affect prognosis, and there should be at least 10 endpoints per variable. Thus we anticipate that recruitment of ≥3000 participants with 200--250 end events will ensure adequate statistical power.

Ethics and dissemination {#s2j}
------------------------

### Ethical approval {#s2j1}

All the participants gave written informed consent before recruitment. The study is non-invasive and imposes no significant risks to participants. Participants can withdraw from the study at any point with no effect on their clinical care. All data are anonymous and managed confidentially and anonymously.

### Dissemination {#s2j2}

The findings of the study will be published in peer-reviewed journals and will be presented at national or international conferences.

Discussion {#s3}
==========

The ageing of the general population means that elderly people now account for a much greater proportion of patients with, or at risk of, CKD. It is reported that CKD affects 30% of adults older than 70 years and 50% of adults older than 80 years.[@R31] The increasing prevalence of CKD in older adults highlights the need for more discerning medical management.

Previous findings indicate that age is an important effect modifier of the course of CKD. One large-scale study showed that, among patients of all ages with CKD, eGFR inversely correlated with both ESRD and mortality. However, at a given level of eGFR, compared with younger patients, the elderly had higher rates of death and lower rates of ESRD.[@R32] These findings suggest that a uniform age-neutral approach is not appropriate for the management of elderly patients with CKD. In younger patients, a low eGFR is likely to result from a single disease affecting the kidney and thus may better predict renal outcomes. But in older patients, low eGFR appears to be a marker for various age-related coexisting conditions and a predictor of global health outcomes (eg, mortality), rather than specific renal outcomes.

Much heterogeneity exists among older adults of a similar age and eGFR regarding coexisting conditions and geriatric syndromes. This complicates CKD management and limits the utility of a single approach that may work well in younger populations. For example, a study from the USA showed that, for adults ≥75 years of age, the presence of multiple non-disease-specific problems was associated with lower eGFR and higher ACR levels, where non-disease-specific problems included cognitive impairment, depressive symptoms, exhaustion, falls, impaired mobility and polypharmacy. Furthermore, the risk of death, hospitalisation and emergency department visits also correlated with the number of non-disease-specific problems. This suggests that the identification of non-disease-specific problems may provide credible risk factors of mortality, independent of kidney function among older patients with CKD.[@R33] In our present study, we focus on the following five non-disease-specific problems as part of geriatric assessment: cognitive impairment, depressive symptoms, nutritional status, impaired mobility and quality of life.

The prevalence of CKD increases with age. Similarly, cognitive impairment is more common in the elderly. Several studies have investigated the association between CKD and cognitive impairment. The Cardiovascular Health Cognition Study[@R34] reported a 37% increased risk of incident dementia in elderly individuals with an elevated Scr concentration. Another cross-sectional study of 1015 women with a mean age of 66.7±6.4 years showed that eGFR was associated with performance on tests of global cognitive function, executive function, language and memory. Individuals with an eGFR \<30 mL/min/1.73 m^2^ were fivefold more likely to have cognitive impairment than those with an eGFR \<60 mL/min/1.73 m^2^.[@R35] The mechanisms that link CKD with cognitive impairment may include anaemia, oxidative stress, lipid and homocysteine metabolic dysregulation, and increased levels of inflammatory cytokines. There is some evidence that cognitive impairment predicts death and disability among the general elderly population[@R36] and dialysis patients.[@R38] However, in elderly patients with predialysis CKD, little is known about whether cognitive impairment is associated with poor outcomes.

Depression is another common phenomenon in patients with late-stage CKD and ESRD. The prevalence of major depression and depressive symptoms varies from 15% to 45% in patients with ESRD or receiving dialysis.[@R39] In several cross-sectional studies,[@R41] those with severe CKD (ie, with an eGFR \<30 mL/min/1.73 m^2^) had more depressive symptoms than those with eGFR ≥60 mL/min/1.73 m^2^. Data have also shown that depression contributes to adverse outcomes in patients with ESRD, including higher risks of mortality, hospitalisation and cardiovascular events.[@R43] However, the number of population-based and longitudinal studies on depression in elderly patients with predialysis CKD is limited.[@R45] The present study intends to include in its analysis the baseline prevalence of depression and its association with adverse outcomes at follow-up. We hypothesised that depressive symptoms among the elderly population with CKD may be related with cognitive impairment, poorer quality of life and increased mortality.

PEW is prevalent in dialysis patients and in patients with predialysis CKD,[@R47] and is associated with high mortality rates.[@R49] Several indicators of PEW may predict cardiovascular events and mortality, such as serum albumin, prealbumin levels, subjective global assessment score and handgrip strength.[@R30] One study of 1220 men with non-dialysis-dependent CKD showed that mortality was positively associated with white blood cell count, and negatively associated with albumin and lymphocyte percentage. Handgrip strength was also found to be a reliable nutritional marker in dialysis patients, and low handgrip strength predicted mortality.[@R51]

Malnutrition and inflammation are highly prevalent conditions in patients with CKD and intimately linked with PEW. The severity of malnutrition and inflammation can be assessed by the MIS scale. For example, during a follow-up of a median of 30 months (18--37 months), patients with higher MIS were at increased risk of mortality in both crude and adjusted Cox models, and PEW is more common in older patients.[@R52] However, there is less information on the prevalence and magnitude of PEW in elderly patients with CKD, and the validity of PEW parameters as renal outcome predictors for this population has not been established. In the present study, the prevalence of PEW in older patients with CKD will be determined, and an association between the indicators of PEW and clinical outcomes will be investigated.

Patients who are under dialysis treatment have reduced levels of physical functioning. This and low physical activity predict poor outcomes.[@R54] It is well known that older adults experience limitations in physical performance, which are associated with disability, healthcare utilisation and mortality.[@R55] But relatively little is known about the disabilities of elderly patients with predialysis CKD. A cross-sectional survey demonstrated that both mild and moderate CKD were associated with higher prevalence of disability. Age and other comorbid conditions account for most, but not all, of these associations, particularly among older adults. But the cross-sectional design of this study did not allow the inference of a causal relationship between disability and clinical outcomes such as death and decline in renal function.[@R58] Thus, in the present study we aim to assess physical function and functional activity among elderly patients with predialysis CKD, and further investigate an association of disability and outcomes.

Persons with ESRD have poorer HRQOL compared with the general population,[@R59] and poor HRQOL is associated with a higher risk of death and hospitalisation.[@R60] However, there have been few studies that investigated the relationship between diminished HRQOL and adverse outcomes among patients with predialysis CKD.[@R62] In the African American Study of Kidney Disease and Hypertension study, low baseline physical and mental HRQOL was associated with a higher risk of cardiovascular events and death, but not associated with CKD progression.[@R63] In another study of 3837 participants with mild to severe CKD, the risk of cardiovascular events and death was independently associated with low physical component summary, effects and symptoms subscales, and risk of death was independently associated with low mental component summary subscale. However, none of the subscale scores were associated with CKD progression.[@R64]

Because of comorbidity and side effects of treatment, older patients with CKD are more likely to have poor HRQOL. HRQOL should be recognised as an important parameter of patient-centred care in elderly patients with CKD. In the present study, the KDQOL-36 will be used to analyse the demographic and clinical factors associated with low baseline HRQOL, and examine the association between baseline HRQOL and the risk of CKD progression, cardiovascular events and death.

A series of measures were included to minimise potential variation in results among the sites: (1) The relevant staff member of each centre was trained before the start of the study. (2) A manual of procedure was drawn up and distributed to each investigator, and detailed instructions are displayed in a uniform and standard manner. (3) An electronic database was established, and each site was asked to enter the data in a timely manner. (4) The quality of data is under the supervision of a professional research organisation composed of senior nephrologists, biostatisticians and an epidemiologist. Every month, 5%--10% of the cases from each participating site are selected randomly, and the validity of the data and questionnaires is checked. Unqualified data are returned to the investigators and recollected or refilled. Investigators will undergo repeated training, as necessary.

This study has some limitations. We recruited subjects based on a single measure of Scr and/or albuminuria without a 3-month interval. Second, there is no fully established eGFR equation to evaluate kidney function in the elderly. Third, there are potential selection bias or confounder effects because the study cohort is from tertiary hospitals instead of communities. We also excluded participants with severe impaired function, who were unable to complete the study procedure even if assisted. Therefore, the generalisability of the results to other populations may be compromised. Finally, the observational design precludes causality.
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